The 36-month beta value for VTAK is also noteworthy at -0.36. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for VTAK is 2.41M, and at present, short sellers hold a 2.17% of that float. The average trading volume of VTAK on October 01, 2024 was 209.24K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VTAK) stock’s latest price update
Catheter Precision Inc. (AMEX: VTAK)’s stock price has gone decline by -8.41 in comparison to its previous close of 0.43, however, the company has experienced a -13.92% decrease in its stock price over the last five trading days. accesswire.com reported 2024-09-24 that FORT MILL, SC / ACCESSWIRE / September 24, 2024 / Catheter Precision, Inc. (VTAK:NYSE/American), a company engaged in the development and marketing of technologically advanced products for the cardiac electrophysiology market, today announced that has received notification of the issuance of its first LockeT patent in the country of China. Locket is a suture retention device used in the closure of percutaneous catheter access sites during any number of catheter procedures including electrophysiology, structural heart, and vascular surgery procedures.
VTAK’s Market Performance
VTAK’s stock has fallen by -13.92% in the past week, with a monthly drop of -70.95% and a quarterly drop of -89.60%. The volatility ratio for the week is 16.23% while the volatility levels for the last 30 days are 21.24% for Catheter Precision Inc. The simple moving average for the past 20 days is -13.06% for VTAK’s stock, with a -89.96% simple moving average for the past 200 days.
Analysts’ Opinion of VTAK
Many brokerage firms have already submitted their reports for VTAK stocks, with Piper Jaffray repeating the rating for VTAK by listing it as a “Neutral.” The predicted price for VTAK in the upcoming period, according to Piper Jaffray is $1.50 based on the research report published on August 13, 2019 of the previous year 2019.
Maxim Group, on the other hand, stated in their research note that they expect to see VTAK reach a price target of $23. The rating they have provided for VTAK stocks is “Buy” according to the report published on November 02nd, 2018.
VTAK Trading at -68.29% from the 50-Day Moving Average
After a stumble in the market that brought VTAK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.30% of loss for the given period.
Volatility was left at 21.24%, however, over the last 30 days, the volatility rate increased by 16.23%, as shares sank -33.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -85.37% lower at present.
During the last 5 trading sessions, VTAK fell by -13.92%, which changed the moving average for the period of 200-days by -91.65% in comparison to the 20-day moving average, which settled at $0.4446. In addition, Catheter Precision Inc. saw -90.23% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VTAK starting from JENKINS DAVID A, who purchase 9,528 shares at the price of $0.60 back on Jan 23 ’24. After this action, JENKINS DAVID A now owns 329,856 shares of Catheter Precision Inc., valued at $5,694 using the latest closing price.
JENKINS DAVID A, the Executive Chairman and CEO of Catheter Precision Inc., purchase 9,528 shares at $0.43 during a trade that took place back on Jan 22 ’24, which means that JENKINS DAVID A is holding 320,328 shares at $4,092 based on the most recent closing price.
Stock Fundamentals for VTAK
Current profitability levels for the company are sitting at:
- -24.45 for the present operating margin
- -0.26 for the gross margin
The net margin for Catheter Precision Inc. stands at -21.77. The total capital return value is set at -0.46. Equity return is now at value -49.81, with -30.71 for asset returns.
Based on Catheter Precision Inc. (VTAK), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -0.82.
Currently, EBITDA for the company is 45.82 million with net debt to EBITDA at -1.09. When we switch over and look at the enterprise to sales, we see a ratio of 24.03. The receivables turnover for the company is 4.15for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.12.
Conclusion
In summary, Catheter Precision Inc. (VTAK) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
